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Abstract
Background: We previously reported the usefulness of the Gal epitope as a target molecule for
gene therapy against cancer. To induce cancer cell specific transcription of the Gal epitope, an
expression vector which synthesizes the Gal epitope under the control of a promoter region of
the human telomerase reverse transcriptase (hTERT), NK7, was constructed.
Methods: NK7 was transfected into a human pancreatic carcinoma cell line, MIA cells, and
telomerase-negative SUSM-1 cells served controls. Expression of the Gal epitope was confirmed
by flow cytometry using IB4 lectin. The susceptibility of transfected MIA cells to human natural
antibodies, was examined using a complement-dependent cytotoxic cross-match test (CDC) and a
flow cytometry using annexin V.
Results: The Gal epitope expression was detected only on the cell surfaces of NK7-transfected
MIA cells, i.e., not on naive MIA cells or telomerase negative SUSM-1 cells. The CDC results
indicated that MIA cells transfected with NK7 are susceptible to human natural antibody-mediated
cell killing, and the differences, as compared to NK-7 transfected telomerase negative SUSM-1 cells
or telomerase positive naïve MIA cells, were statistically significant. The flow cytometry using
annexin V showed a higher number of the apoptotic cells in NK-7 transfected MIA cells than in
naïve MIA cells.
Conclusions: The results suggest that Gal epitope-expression, under the control of the hTERT-
promoter, may be useful in cancer specific gene therapy.
Introduction
One of the common difficulties commonly encountered
in cancer gene therapy is manipulation of a gene which
acts exclusively in cancer cells, without affecting normal
cells. For instance, transfecting suicide-gene, such as mem-
bers of the caspase family, in order to induce apoptosis
should affect only cancer cells, not normal cells. For this
reason, cancer specific transcription of a transfected gene
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driven by a promoter region of human telomerase reverse
transcriptase (hTERT) has recently been reported [1,2].
Telomerase is a ribonuclear protein complex that has
hTERT as a catalytic domain. The recent cloning of both
hTERT and the RNA component (hTERC) of human tel-
omerase [3,4] has provided an opportunity to directly in-
vestigate the role of telomerase and telomere maintenance
in the replicative life span of a cell. While hTERC is abun-
dantly expressed in both normal and tumor cells, hTERT
expression was shown to correlate with telomerase activi-
ty, suggesting that hTERT is the limiting component of the
enzyme. In normal human tissues, telomerase is detected
only in germ cells, lymphocytes, endometrial cells, kerati-
nocytes and intestinal cryptic cells, most human somatic
cells do not express the activity of this enzyme [5]. On the
other hand, telomerase activity is detected in approxi-
mately 90% of human cancer cells of various origins [6–
8]. The promoter region of hTERT has been cloned [9–
11]. The ubiquitous transcription of telomerase in cancer
cells may be partially controlled by the function of the
hTERT promoter. As mentioned above, the hTERT pro-
moter region has been used as tumor specific promoter in
several studies [1,2].
The Gal epitope is known to be a major xeno-antigen
[12]. Humans and Old World Monkeys do not have the
Gal epitope, having instead, anti-Gal antibodies, i.e.,
natural antibodies. The Gal epitope, when expressed on
the cell surface, binds to natural antibodies in human se-
rum. This binding activates the complement cascade,
leading to complement dependent cell lysis [13].
The Gal epitope is synthesized by the enzyme 1–3 ga-
lactosyltransferase (1–3 GT) [14]. We previously dem-
onstrated transfection of the bovine 1–3 GT gene and
expression of the Gal epitope to transform human pan-
creatic and hepatocellular cancer cell lines, making them
be susceptible to natural antibody-mediated cell lysis
[15]. In that study, bovine 1–3 GT was transcribed under
the control of the cytomegalovirus immediate-early pro-
moter (CMVIE), which exerts effects not only on cancer
cells but also a variety of normal cells.
In the present study, we constructed the vector, NK7 (Fig.
1), in which transcription of the bovine 1–3 GT gene was
driven by the hTERT promoter. The transfection of NK7
into human cancer cell line brought about expression of
the Gal epitope only in telomerase-positive cancer cells.
Results
Transcriptional activity of the hTERT gene promoter
Transcriptional activity of the hTERT gene promoter,
which we cloned, was tested in luciferase assays (Fig. 2).
The hTERT gene promoter showed approximately twofold
higher than that of the pGL3-Basic Vector (Promega).
These results indicated that the cloned hTERT gene pro-
moter was fully functional.
1–3 GT driven by the hTERT promoter was functional in 
human pancreatic cancer cells
As described in Methods, SUSM-1 cells were shown to be
negative for the telomerase-activity. The Gal epitope was
not detected on the cell surfaces of either naïve or NK7-
transfected SUSM-1 cells (Fig. 3A,3B). Naïve MIA cells did
not show a positive log shift for the Gal epitope (Fig.
3C). On the other hand, NK7-transfected MIA cells
showed a high positive log shift for the Gal epitope (Fig.
3D). These results indicate that the hTERT promoter acts
only on MIA cells, which are telomerase-positive, i.e., not
on SUSM-1 cells which are telomerase-negative.
Figure 1
Diagram of NK7. Transcription of bovine 1–3 GT is driven by the hTERT gene promoter
hTERT Promoter α1-3 GT
SV40 Enhancer SV40 Promoter NEORCancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/14
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The transfection of NK7 transformed human pancreatic 
cancer cells to be susceptible to antibody-mediated cell 
killing
Next, the susceptibility of NK7-transfected MIA cells to
human natural antibody-mediated cell lysis was exam-
ined by CDC. Naïve SUSM-1, naïve MIA cells and NK7-
transfected SUSM-1 cells were resistant to natural anti-
body-mediated cell lysis (Fig. 4A). In contrast, NK7-trans-
fected MIA cells were effectively lysed by human natural
antibodies (Fig. 4B). A comparison of the percentages of
dead cells among CDC assays is shown in Table 1. The
number of dead cells was significantly higher in NK7-
transfected MIA cells than in naive MIA cells, NK7-trans-
fected SUSM-1.
Next, the involvement of the apoptosis in the mechanism
of our model was examined by flow cytometry, because in
rat model, it is known that activation of complements it-
self can induce apoptosis in target cells. Naïve MIA cells
did not show a positive log shift for the Gal epitope,
whereas NK-7 transfected MIA cells showed a positive log
shift for annexin V (Fig. 5B).
Discussion
In a previous study, we found that human cancer cell
lines, which had been transfected with the bovine 1–3
GT gene, were effectively killed by circulating human nat-
ural antibodies [15]. In that study, transcription of the bo-
vine 1–3 GT gene was driven by CMVIE. This promoter is
expected to work in all cell types. Clearly, a vector which
exerts its effects exclusively in cancer cells was essential.
The present study demonstrated the hTERT gene-promot-
er to be capable of driving the transcription of the trans-
fected 1–3 GT gene in telomerase-positive MIA cells, but
not in telomerase-negative SUSM-1 cells.
The mechanism of by which the Gal epitope and human
natural antibodies produce cell lysis is mainly comple-
ment-mediated [13]. Human cells have complement reg-
ulatory molecules on their cell surfaces which inhibit
uncontrolled activation of the complement cascade. These
molecules are known to play important roles in human
disease [16]. There are diseases in which activated comple-
ment components overcome the inhibitory effects of
complement regulatory molecules [17]. For instance, red
blood cells are lysed when blood from a donor with a dif-
ferent blood type is transfused, even though red blood
cells have complement regulatory factors including CD55
and CD59 on their cell surfaces. Complement compo-
nents and complement regulatory molecules are balanced
in the healthy state. In the present study, we used NK7-
transfected MIA cells which showed relatively high expres-
sion of the Gal epitope by flow cytometry. The previous
study suggests that complement-activation induce apop-
tosis in cells [18]. Although annexin V staining does not
distinguish strictly apoptosis from necrosis (Fig. 5), apop-
tosis may play a role in complements-dependent cell
deaths.
As shown in Figure 3, NK7-transfected MIA contained
Gal-negative cells. It is known that the activity of telom-
erase depend on the cell-cycle [19]. The stage of the cell cy-
cle of NK7-transfected MIA cells so varied and that may
have had the influence on the strength of the activity of
the expression of the Gal-epitope.
The 1–3 GT gene was inactivated by a point mutation
and became a pseudogene in humans and old world mon-
keys [20]. Instead, humans have abundant anti-Gal anti-
bodies, i.e. natural antibodies. Our strategy for anti-cancer
gene therapy is to induce abundant expression of the Gal
epitope only on the cell surfaces of cancer cells. Once this
is achieved, it is anticipated that the cancer cell will be
lysed by natural antibodies which already exist in the hu-
man body. As long as expression of the Gal epitope re-
Figure 2
HTERT promoter activity in MIA cells. Control: pGL3-Con-
trol Vector (Promega). Basic: pGL3-Basic Vector (Promega).
PhTERT: hTERT gene promoter subcloned to pGL3-Basic
Vector. Relative activities are expressed as means  SD.
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mains cancer cell specific, using the hTERT gene promoter
region as a gene-promoter of the 1–3 GT gene is a prom-
ising treatment strategy.
To apply our construct to clinical gene therapy, expression
of the Gal epitope must be adequate to overcome the ac-
tions of complement regulatory molecules. Strategies to
enhance this expression or somehow modify complement
biology, to increase the sensitivity of complement-medi-
ated cell lysis, are thus needed.
Methods
Construction of NK7
The full length bovine 1–3 GT cDNA was cut at Apa- and
BamH-sites of N3GA [15] and ligated to an pEGFP-1 vec-
tor (CLONTECH, Palo Alto, CA) to form an E1GA vector.
The hTERT promoter region was amplified by PCR and
subcloned, as previously described [11]. Briefly, genomic
Figure 3
Detection of Gal epitope by flow cytometry. Using FITC-conjugated IB4 lectin, the Gal epitope was detected on NK7-trans-
fected MIA cells (D), but not on naïve SUSM-1 cells (A), NK7-transfected SUSM-1 cells (B), or naïve MIA cells (C). (Dotted
line; unstained. Solid line; stained).
(A) (B)
(C) (D)
Table 1: Results of complement dependent cytotoxic cross 
match-test
Naïve (%) NK7-transfected (%)
SUSM-1 25.3  5.5 22.7  12.7
MIA 20.5  8.1 79.7  5.1
Percentages shown are of dead cells analyzed by the complement-
dependent cytotoxic cross-match test. The results are presented as 
means  SD from three independent experiments. () indicates a sta-
tistically significant difference between NK7-transfected MIA cells and 
other cells (ANOVA: p < 0.05).Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/14
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DNA was extracted from human pancreatic carcinoma cell
line, MIA PaCa-2 [21]. Then, 100 ng of genomic DNA
were amplified by PCR using Gene Taq (Nippon gene, To-
kyo, Japan). The following primer sequences were used
for PCR: 5-TCTGGATTCCTGGGAAGTCCTCA-3, 5-ACG-
CAGCGCTGCCTGAAACTCG-3. A 1082-bp PCR product
was subcloned into the pGEM-T vector (Promega, Madi-
son, WI). The fragment was cut at Sal- and Sph-sites and
ligated to a pSP72 vector (Promega), then cut at Xho- and
Kpn-sites and finally ligated to the E1GA vector (NK7, Fig-
ure 1).
Dual luciferase assay
The luciferase reporter plasmid was constructed by sub-
cloning of the hTERT promoter region to Kpn I and Bgl II
sites in the pGL3-Basic vector (Promega). MIA cells were
seeded at 3  104 per 16-mm well and transfected 24 h lat-
er with complexes containing 1.2–1.9 l of Lipo-
fectAMINE, 4 l Plus reagent (GIBCO, Rockville, MD)
which contained the Renilla luciferase gene as a transfec-
tion efficiency control, and 420 ng of firefly luciferase re-
porter plasmid per well. Lysates were prepared 24–48 h
after transfection by adding 100 l of reporter lysis buffer
(dual luciferase reporter system, Promega), and their luci-
ferase activities were measured with an analytical lumi-
nometer (model TD-20/20, Turner Designs, Sunnyvale,
CA) and expressed as relative luciferase units (RLU), cal-
culated by determining the ratio of the intensity of the
light produced by the Renilla luciferase pRL-TK plasmid.
All luciferase assays were performed in triplicate.
Cell lines and transfection
MIA cells and SUSM-1 cells [22] were used. SUSM-1 cells
were negative for telomerase-activity, such that the hTERT
gene-promoter was expected to not be active in SUSM-1
cells. Cells were cultured in Dulbecco's modified eagle
Figure 4
Complement dependent cytotoxic cross-match test NK7-transfected SUSM-1 cells (A) were resistant, while NK7-transfected
MIA cells (D) were susceptible, to complement-mediated cell lysis. Dead cells appeared darker than living cells. Naïve SUSM-1
and naïve MIA cells showed similar results as that of NK7-transfected SUSM-1 cells.
(A)
(B) (B)Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/14
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medium (GIBCO), containing 10 % fetal calf serum in a
5% CO2 incubator. Twenty micrograms of NK7 were elec-
troporetically transfected into 2  106 cells with a GENE
PULSER (BIO RAD, Hercules, CA). Approximately 1  103
cells per well were cultured in a medium containing neo-
mycin (Geneticin, GIBCO), in a 96-well plate, for 10–14
days. The neomycin concentrations for the selection of
MIA cells and SUSM-1 cells were 1 mg/ ml and 0.4 mg/
ml, respectively. Individual neomycin resistant clones
were picked up and transferred to a 24 well tissue culture
plate, and DNA extracted from these cells was subjected to
PCR to confirm integration of the 1–3 GT cDNA. PCR
was performed using the following primers. Sense strand
primer: 5'-AGCTCAGTAGAACTTGGTACTTTT-3', and
anti-sense strand primer: 5'-CATCTGATTACCACAGGT-
TCATT-3'. After an initial denaturation for 3 minutes at
94C, amplification was performed for 25 cycles in a final
volume of 50 l using 2.5 u of Taq DNA polymerase. Each
cycle consisted of 30 seconds at 94C, 30 seconds at 60C
and 60 seconds at 72C. The PCR products were separated
by 2% agarose gel electrophoresis and the products were
visualized by ethidium bromide. Ten neomycin-resistant
clones from MIA cells or SUSM-1 cells, which were posi-
tive for the 1355 bp-PCR product, were transferred to 10-
cm tissue culture plates to obtain a sufficient number of
cells for flow cytometry and complement dependent
cross-match test (CDC).
Flow cytometry
The promoter activity of the hTERT gene was expected to
operate in the endogenously telomerase-positive MIA
cells, but not in the telomerase-negative SUSM-1 cells.
Promoter activity was reflected by detection of the Gal
epitope on the MIA cell surface, in cells which had been
efficiently transfected with NK7. The Gal epitope was de-
tectable by flow cytometry using FITC-conjugated BS-I
Figure 5
Flow cytometry using annexin V (A) Red colored cells were analyzed by histogram. X-axis: Forward scatter. Y-axis: Side sact-
ter. (B) Apoptosis was induced in NK-7 transfected MIA (solid line) by human natural antibodies and complements. Naïve MIA
cells (dotted line).
(A) (B)Cancer Cell International 2002, 2 http://www.cancerci.com/content/2/1/14
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ISOLECTIN B4 (IB4 lectin, Sigma, St. Louis, MO). IB4 lec-
tin recognizes the terminal galactosyl epitope in the 
linkage [23]. Flow cytometry was performed as follows.
Approximately, 1  106 cells were incubated in 10 g of
IB4 lectin. After a 60-min incubation, the cells were
washed twice with PBS, and analyzed on a FACscan (Bec-
ton-Dickinson, Mountain View, CA).
Complement dependent cytotoxic cross-match test (CDC)
As previously reported, we used a CDC assay to examine
the susceptibility of transfected cells to antibody-mediat-
ed cell lysis [14]. Approximately 2  106 cells were cul-
tured with 50 l of human serum at 37C. To exclude the
possible involvement of anti-blood type antibodies,
pooled human sera from blood types A, B, O and AB do-
nors were used as the source of natural antibodies, at each
experiment. After a 50-min incubation, 5 l of rabbit com-
plement were added to the plates and a further 70-min in-
cubation was carried out. Then, a 5 % eosin solution was
added to the plates, and dead cells which appeared darker
than the living cells were counted under a microscope. In
each experiment, the three wells containing the highest
number of dead cells were selected, and the percentage of
dead cells was calculated. The ANOVA was used for the
statistical analysis. CDC assays were performed on the
same day of the flowcytometry.
Evaluation of apoptosis by the annexin V binding assay
The annexin V binding assay was performed using the An-
nexin V-FITC Apoptosis Detection kit (PharMingen) ac-
cording to the supplier's instruction. At least 1  106 cells
prepared by human serum and rabbit complement de-
scribed in CDC were incubated with FITC-conjugated an-
nexin V at room temperature for 15 min. The cells were
then analyzed by flow cytometry.
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